Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 20;12:839816. doi: 10.3389/fonc.2022.839816

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Reichrath, Biersack, Wagenpfeil, Schöpe, Pföhler, Saternus and Vogt

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

25(OH)D s.c. are associated with frequency of adverse events (AEs) in patients treated for advanced melanoma with BRAF, MEK, and/or immune checkpoint inhibitors. Analyzing the complete cohort of melanoma patients included in this study, vitamin D status was not associated with a significantly altered frequency of AEs (estimated as AE ratio that was calculated as described in the Methods). However, there was a trend for reduced frequency of AEs (AE ratio -0.18) in patients with average 25(OH)D serum concentrations ≥10 ng/ml as compared to severely vitamin D deficient individuals [average 25(OH)D serum concentration <10 ng/ml] (p = 0.303).